81167-39-7

Basic information

• Product Name: N-(DIPHENYLMETHYLENE)GLYCINE METHYL ESTER
• Synonyms: DPM-Gly-OMe;(N,N-diphenylmethylgene)glycine methyl ester;N-(DIPHENYLMETHYLENE)GLYCINE METHYL ESTER;(Benzhydrylideneamino)acetic Acid Methyl Ester;Benzophenoneimine glycine Methyl Ester;Methyl 3-aza-4,4-diphenylbut-3-enoat;Methyl 3-aza-4,4-diphenylbut-3-enoate;Methyl N-(diphenylmethylene)glycinate
• CAS NO: 81167-39-7
• Molecular Formula: C₁₆H₁₅NO₂
• Molecular Weight: 253.2958
• EINECS: 1533716-785-6
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives
• Mol File: 81167-39-7.mol
• Article Data: 35

Chemical Properties

• Melting Point: 42-44?C
• Boiling Point: 342.8oC at 760 mmHg
• Flash Point: 135.8oC
• Appearance: White to pale yellow/Solid
• Density: 1.05g/cm3
• Vapor Pressure: 7.36E-05mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• PKA: 2.22±0.50(Predicted)
• CAS DataBase Reference: N-(DIPHENYLMETHYLENE)GLYCINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-(DIPHENYLMETHYLENE)GLYCINE METHYL ESTER(81167-39-7)
• EPA Substance Registry System: N-(DIPHENYLMETHYLENE)GLYCINE METHYL ESTER(81167-39-7)

Safety Data

• Hazardous Substances Data: 81167-39-7(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Pale Yellow Solid

Uses

N-(Diphenylmethylene)glycine Methyl Ester (cas# 81167-39-7) is a compound useful in organic synthesis.

Synthesis Reference(s)

Tetrahedron Letters, 23, p. 2863, 1982 DOI: 10.1016/S0040-4039(00)88434-8

InChI:InChI=1/C16H15NO2/c1-19-15(18)12-17-16(13-8-4-2-5-9-13)14-10-6-3-7-11-14/h2-11H,12H2,1H3

Upstream product

• 1013-88-3 Benzophenone imine 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 1816-92-8 Methyl azidoacetate 
• 1450-31-3 Thiobenzophenon 
• 96-32-2 bromoacetic acid methyl ester 
• 119-61-9 benzophenone 

Downstream Products

• 144150-91-4 (E)-2-(Benzhydrylidene-amino)-4-vinyl-dodec-4-enoic acid methyl ester 
• 104706-70-9 (1S,2S)-2-[(Benzhydrylidene-amino)-methoxycarbonyl-methyl]-cyclopropanecarboxylic acid methyl ester 
• 104706-75-4 (E)-5-(Benzhydrylidene-amino)-hex-2-enedioic acid dimethyl ester 
• 119825-62-6 (S)-2-(Benzhydrylidene-amino)-2-methyl-pent-4-enoic acid methyl ester 
• 119825-62-6 (R)-2-(Benzhydrylidene-amino)-2-methyl-pent-4-enoic acid methyl ester 
• 118169-12-3 (R)-methyl 2-((diphenylmethylene)amino)pent-4-enoate 
• 118169-13-4 (S)-methyl 2-((diphenylmethylene)amino)pent-4-enoate 
• 119825-51-3 methyl N-(diphenyl methylene)-2-2-cyclohexenyl glycinate 
• 145243-37-4 2-(Benzhydrylidene-amino)-3-(2-chloro-phenyl)-propionic acid methyl ester 
• 145243-38-5 2-(Benzhydrylidene-amino)-3-(3-chloro-phenyl)-propionic acid methyl ester 
• 118169-12-3 Methyl 2-(benzhydrylideneamino)-4-pentenoate 

Relevant articles and documents

Synthesis of fluorescent dipeptidomimetics and their ribosomal incorporation into green fluorescent protein

The synthesis and incorporation into position 66 of green fluorescent protein (GFP) by in vitro protein translation of novel oxazole and thiazole based dipeptidomimetics are described. The compounds may be regarded as GFP chromophore analogues, and are strongly fluorescent. An α-amido-β-ketoester intermediate was obtained via bisacylation of a protected glycine. The intermediate underwent dehydrative cyclization to afford the 1,3-oxazole and was treated with Lawesson's reagent to furnish the 1,3-thiazole. When these fluorophores were introduced into position 66 of GFP in place of Tyr66, the resulting GFP analogues exhibited fluorescence emission several-fold greater than wild-type GFP; the emission was also shifted to shorter wavelength. It may be noted that compared to the typical fluorophores formed in the natural and modified fluorescent proteins, the oxazole and thiazole fluorophores are completely stable and do not require activation by posttranslational modification to exhibit fluorescence.

NOVEL OPIOID ANTAGONISTS AND METHODS RELATED THERETO

Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and fibromyalgia. The novel gliotoxin analog compound acts by acting as an antagonist to one or more opioid receptors, which, when present leads to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner.

PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-A]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE

The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.